Altium Capital Management LP Buys Shares of 35,000 Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

Altium Capital Management LP bought a new stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 35,000 shares of the company’s stock, valued at approximately $3,182,000. Reata Pharmaceuticals makes up 1.8% of Altium Capital […]

Related Keywords

China ,Leerink Partnrs ,Manmeet Singh Soni ,Securities Exchange Commission ,Nasdaq ,Reata Pharmaceuticals ,China Universal Asset Management Co ,Cantor Fitzgerald ,Jefferies Financial Group ,Reata Pharmaceuticals Inc ,News Ratings For Reata Pharmaceuticals Daily ,Reata Pharmaceuticals Company Profile ,Exchange Commission ,Reata Pharmaceuticals Trading ,International Assets Investment Management ,Advisor Group Holdings Inc ,Us Bancorp ,Belpointe Asset Management ,Quarter For Reata Pharmaceuticals ,Altium Capital Management ,Free Report ,Capital Management ,Asset Management ,Assets Investment Management ,Universal Asset Management ,Group Holdings ,Director Shamim Ruff ,Singh Soni ,Get Free Report ,Visit Holdingschannel ,Reata Pharmaceuticals Daily ,Nasdaq Reta ,Greta ,Medical ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,